LY007

LY007 is a novel anti-CD20 chimeric antigen receptor T cell (CAR-T) therapy developed for the treatment of relapsed or refractory CD20-positive B-cell non-Hodgkin lymphoma. It is designed to target the CD20 antigen on malignant B cells and incorporates both OX40 and 4-1BB co-stimulatory domains to enhance CAR-T cell proliferation and cytotoxicity. The drug has demonstrated tolerability and a favorable dose-response relationship in phase 1 clinical trials, with ongoing evaluation of its safety, pharmacokinetics, pharmacodynamics, efficacy, and immunogenicity in this patient population[1][3][5][7].

Other names

anti-CD20 CAR-T cellsanti-CD-20 CAR-T cellsanti-CD 20 CAR-T cellsCD20-targeting CAR T cellsCD-20-targeting CAR T cellsCD 20-targeting CAR T cellsShanghai Longyao CD20 CAR-T